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Abstract
Background: Before a new test is introduced in clinical practice, evidence is needed to demonstrate that its use
will lead to improvements in patient health outcomes. Studies reporting test accuracy may not be sufficient, and
clinical trials of tests that measure patient health outcomes are rarely feasible. Therefore, the consequences of
testing on patient management are often investigated as an intermediate step in the pathway. There is a lack of
guidance on the interpretation of this evidence, and patient management studies often neglect a discussion of the
limitations of measuring patient management as a surrogate for health outcomes.
Methods: We discuss the rationale for measuring patient management, describe the common study designs and
provide guidance about how this evidence should be reported.
Results: Interpretation of patient management studies relies on the condition that patient management is a valid
surrogate for downstream patient benefits. This condition presupposes two critical assumptions: the test improves
diagnostic accuracy; and the measured changes in patient management improve patient health outcomes. The
validity of this evidence depends on the certainty around these critical assumptions and the ability of the study
design to minimise bias. Three common designs are test RCTs that measure patient management as a primary
endpoint, diagnostic before-after studies that compare planned patient management before and after testing, and
accuracy studies that are extended to report on the actual treatment or further tests received following a positive
and negative test result.
Conclusions: Patient management can be measured as a surrogate outcome for test evaluation if its limitations
are recognised. The potential consequences of a positive and negative test result on patient management should
be pre-specified and the potential patient benefits of these management changes clearly stated. Randomised
comparisons will provide higher quality evidence about differences in patient management using the new test
than observational studies. Regardless of the study design used, the critical assumption that patient management
is a valid surrogate for downstream patient benefits or harms must be discussed in these studies.
Background
Before a new test is introduced in clinical practice, evi-
dence is needed to demonstrate that its use will lead to
improvements in patient health outcomes [1]. Studies
reporting test accuracy may not be sufficient, and clini-
cal trials of tests that follow patients over the whole
pathway from testing to treatment outcomes, although
ideal, are rarely feasible [2]. Therefore, studies investi-
gating the consequences of tests on patient manage-
ment, that is the use of treatment and the ordering of
further tests, are sometimes undertaken to support con-
clusions about test effectiveness. The rationale for these
studies is that a test must change patient management
to provide health benefits, or at least not compromise
management while providing other benefits, such as
improved safety. Interpretation of these studies, how-
ever, presents the fundamental problem that a measured
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improved health outcomes.
The obstacles of using management as a surrogate for
health outcomes were described by Fineberg and collea-
gues [3] in their 1977 study of cranial Computed Tomo-
graphy (CT), one of the first of its kind. They explained
that the impact of CT on therapeutic plans is only a
“way-station measure of clinical efficacy on the path to
patient outcome”.G u y a t te ta l . ’s landmark paper on the
use of diagnostic before-after studies, which compare
planned patient management before and after testing,
provided structured guidance for researchers about the
methodological challenges of patient management studies
[4]. However, a search of the literature indicates that little
methodological work has been done in this field over the
last 25 years. Some guidance exists about the design [5]
and appraisal [6] of diagnostic before-after studies, but
there are no guidelines for researchers on different types
of study design and the interpretation of change in man-
agement as a surrogate for health outcomes.
Unsurprisingly perhaps, there is little consistency in
how evidence about the impact of testing on patient
management is reported and interpreted in the litera-
ture. For example, a study about Positron Emission
Tomography (PET) for various cancers, designed to sup-
port recommendations for funding, briefly mentions that
the intended changes in management measured do not
always go in the correct direction and improve out-
comes [7]. Other current examples, such as studies of
the impact of prognostic markers on the selection of
adjuvant cancer treatments [8], do not caution about
the limitations of this evidence.
Methodological guidance on this topic is an important
area of need for researchers, clinicians and others mak-
ing decisions about the use of tests. A systematic review
of health technology assessments (HTAs) of medical
tests published between 2005 and 2010 demonstrated
that the impact of testing on patient management is fre-
quently assessed, with evidence available from a range
of different study designs including randomised trials,
but interpretation of this evidence for conclusions about
the impact of the test on health outcomes is inconsis-
tently reported [9].
Although researchers can follow standard epidemiolo-
gical principles for intervention studies when designing
studies to measure the effect of a test on patient man-
agement, the interpretation of this endpoint as a surro-
gate for health outcomes raises different unique issues.
In this paper, we explain how the validity of this evi-
dence depends on both the level of certainty surround-
ing assumptions linking changes in patient management
to improved health outcomes and the susceptibility of
different study designs to biases.
Methods
In the absence of guidelines, we developed the ideas
presented in this paper with Fryback and Thornbury’s
widely adopted 6-level hierarchical framework as a start-
ing point [10]. Several modifications of this framework
have been published [11]. Most of these variations share
the same basic hierarchy to rank test evidence according
to the type of outcomes evaluated along the causal path-
way linking testing with treatment outcomes. Together
with test accuracy, they recognise impact on patient
management as an intermediate outcome that is neces-
sary but not sufficient alone to infer change in patient
health outcomes.
For the purpose of this paper, we defined patient man-
agement studies as an empirical study designed to mea-
sure whether information provided by a medical test
changes clinician decisions about treatment or further
investigation.
Following the GRADE system for judging the quality
of evidence for medical tests in terms of their conse-
quences on patient outcomes [1], we identified two
major issues that need to be explored when interpreting
patient management studies: the validity of assumptions
that changes in patient management lead to improved
health outcomes, which are independent of study design,
and the avoidance of bias in the estimates of patient
management, which depends on study design. These
issues are dealt with in turn in the following sections.
We first explain the guiding principles for using patient
management as a surrogate outcome, followed by a
description of the different study designs and key points
for interpretation of results.
Results
Patient management as a surrogate outcome
The Fryback and Thornbury framework [10] recognises
that medical tests are embedded in a clinical pathway.
W eu s eas i m p l i f i e dv e r s i o no ft h ec l i n i c a lp a t h w a y ,
referred to here as the ‘test-treatment pathway’, to illus-
trate the key concepts (Figure 1). This pathway is char-
acterised by the population who will be tested, and the
available tests and management options. It shows that
when a test is claimed to improve patient health out-
comes by improving management decisions, the key
determinants are test accuracy for detecting cases eligi-
ble for a change in management and the effectiveness of
the management. Measuring patient management as a
surrogate outcome involves specifying what changes in
management will occur that are expected to benefit
patients, rather than measuring overall changes in man-
agement. The proposed role of a test within the path-
way, that is whether it will be used as a replacement for
an existing test, as an add-on after existing tests, or
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be stated [12].
Critical assumptions
By definition, patient management studies do not pro-
vide direct evidence about health outcomes. Interpreta-
tion relies on the condition that the outcome measured,
f o re x a m p l es u r g e r yp e r f o r m e df o l l o w i n gat r u e( o r
false) positive test result, is a valid surrogate for down-
stream patient benefits (or harms).
This condition presupposes two critical assumptions:
First, the test improves accuracy, which is important in
order to judge whether changes in patient management
are likely to be based on correct test results. Compara-
tive diagnostic accuracy studies of the existing and new
tests are needed to provide this evidence [12]. These
studies investigate the veracity of test results by compar-
ing the tests with a reference standard. They provide
estimates of the true positive rate (sensitivity) and true
negative rate (specificity) of a test [13].
The second assumption is that the changes in patient
management observed improve patient health outcomes.
Judging whether this assumption is reasonable may some-
times be straightforward, for example if the test reduces
the use of unnecessary invasive tests, but is usually more
complicated and relies on careful assessment of supportive
evidence. This assessment requires expert opinion. Two
common scenarios are discussed below.
Two common scenarios
In the first scenario, the new test is proposed to
improve outcomes by adding treatment for patients test-
ing positive who would not have been detected by exist-
ing tests (Figure 2, top). Judgements are required that
treatment is effective for the additional true positive
findings, and these benefits outweigh the harms of
unnecessary treatment or further testing in false
positives.
If previous trials have demonstrated treatment is effec-
tive for patients identified using existing tests, it may be
possible to extrapolate these findings to the additional
cases detected by the new test [14]. Unfortunately, there
is no simple algorithm to assess generalisability; there-
fore clinical judgement is required. Importantly, the
additional cases are likely to represent a different disease
spectrum to cases detected by the existing tests alone.
Based on the principles used to consider whether trial
evidence can be applied to an individual patient [15],
two necessary assumptions are: i) the baseline risk of
disease events in the new population is high enough to
warrant treatment, and ii) existing trial evidence about
treatment effectiveness can be applied to this popula-
tion. The latter may be considered reasonable if trials
have demonstrated that the relative treatment effects are
similar across a broad disease spectrum. If so, the esti-
mated treatment benefits then need to be weighed up
against the potential harms of false positive findings
(Table 1). However, if a new test detects cases earlier in
the disease process, there may not be sufficient existing
evidence that can be used to extrapolate patient benefits.
To illustrate, a systematic review has shown that Mag-
netic Resonance Imaging (MRI) is more sensitive in
detecting additional breast cancer foci which are occult
on conventional imaging [16]. The authors concluded
that women with true positive MRI findings often
receive more extensive surgery and may potentially ben-
efit from better local tumour control, whereas those
with false positive results have additional biopsies which
may delay treatment and/or result in more breast tissue
excised than necessary, including unnecessary mastect-
omy, leading to poorer cosmetic outcomes. We suggest
it would be helpful to include an explicit statement say-
ing that inferences about the benefits of more extensive
surgery in this MRI classified population would be
strengthened by evidence that this population has a
higher risk of local recurrence than patients testing
negative and that the relative benefits of more extensive
surgery are similar for patients with varying extent of
disease. When there is doubt (and clinical equipoise)
about assumptions of improved health outcomes,
Treatment effectiveness
Test
information
Clinical
classification
Management
decision
Patient health
outcomes
Accuracy
Impact on management
Figure 1 Test-treatment pathway showing Accuracy, Impact on management and Treatment effectiveness as determinants of health
outcomes. Adapted from Staub et al. [9]
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groups are recommended.
In the second scenario, the new test is proposed to
improve patient outcomes by avoiding unnecessary
treatment for patients testing negative who would have
been classified as positive by existing tests (Figure 2,
bottom). Judgements are required that the benefits of
avoiding unnecessary treatment in true negative findings
outweigh the harms of missed or delayed treatment in
false negatives. The same concepts apply when the new
test is proposed to avoid further testing rather than
changing treatment. The benefits of avoiding manage-
ment in true negative findings can be estimated by con-
sidering the risk of adverse events and costs associated
with the treatment (or further testing) that would not
result in any benefits for the patient.
Information about the harms of avoiding management
following a false negative result is usually less readily
Treatment effectiveness
Test
information
Accuracy
Impact on management
Benefits for TN?
Harms for FN?
Existing tests pos
New test neg
Avoid
treatment?
Improved patient 
health outcomes?
Benefits for TP?
Harms for FP?
Existing tests neg
New test pos
Add
treatment?
Improved patient 
health outcomes?
Figure 2 Identifying critical assumptions that changes in patient management improve patient health outcomes. Abbreviations: pos =
positive, neg = negative, TP = true positive, FP = false positive, TN = true negative, FN = false negative
Table 1 Judging whether a change in patient management is likely to improve patient health outcomes
Test claim Improved health outcomes Conclusion Example
Assumption 1 Assumption 2
Test
accuracy
Supportive
evidence
Impact of changed
management on health
outcomes
Supportive
evidence
Adds effective
treatment by
detecting more
cases
(where new test
pos, existing tests
neg)
New test is
more
sensitive
than
existing
tests
(more TP
cases)
Comparative
accuracy
study
Benefits for TP
Absolute treatment benefits
outweigh harms:
i) risk of disease events is
clinically important, and
i) study
measuring
prognosis in test-
stratified
population
Judgement
Evidence supports potential
benefits of treatment for TP,
and these benefits outweigh
harms for FP
Or
Require RCT
Breast MRI
added to
conventional
imaging
ii) relative treatment effects
for TP detected by existing
tests also apply to additional
TP detected by new test
ii) RCT measuring
treatment
effectiveness for
disease
subgroups
Harms for FP
iii) harms of unnecessary
treatment are acceptable
iii) study
measuring risk of
treatment
adverse events
Avoids unnecessary
treatment or further
tests by excluding
more non-cases
(where new test
neg, existing tests
pos)
New test is
more
specific
than
existing
tests
(fewer FP
cases)
Comparative
accuracy
study
Benefits for TN
i) treatment or further tests
carry a risk of adverse events
i) study
measuring risk of
treatment
adverse events
Judgement
Evidence supports benefits of
avoiding treatment or further
tests for TN outweigh
potential harms for FN cases
Or
Require RCT
POC
prothrombin
time versus
clinical
judgement
Abbreviations: pos = positive, neg = negative, TP = true positive, FP = false positive, TN = true negative, FN = false negative, RCT = randomised controlled trial,
MRI = magnetic resonance imaging, POC = Point-of-care
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the risk of adverse events in patients testing negative is
below an acceptable level to infer low risk of harm from
false negatives (Table 1). This can be measured in sin-
gle-arm studies of tested patients or trials that compare
the new test strategy with existing tests. Such trials can
also assess the trade-off between benefits and harms.
For example, point-of-care prothrombin time testing has
been shown to be highly accurate in providing test
results to anaesthesiologists, with minimum delay in the
operating theatre, to make decisions about the use of
blood products in bleeding patients [17]. The investiga-
tors concluded that point-of-care prothrombin time
testing has the potential “to improve patient morbidity
and mortality by: reducing the rate of unnecessary trans-
fusion of fresh frozen plasma and associated complica-
tions in patients testing negative, and reducing major
intra-operative bleeding through earlier detection and
more rapid treatment of coagulopathic patients”.F a l s e
negative test results are not expected to have a major
detrimental effect, becausean e g a t i v et e s tw o u l ds h i f t
rather than replace the clinical threshold for transfusion,
so patients who clearly demonstrate abnormal bleeding
would still receive blood products regardless of a nega-
tive test result. However, it was also concluded that
these assumptions of the impact of the test on patient
management and subsequent outcomes needed confir-
mation, and a trial investigating these questions is
underway [18].
In a third possible scenario, the number of patients
receiving the specified management remains the same
but the new test has other attributes, for example it is
less invasive or less expensive than the existing tests,
with similar accuracy. Conclusions of no change in
management essentially require an assessment of
equivalence to exclude a clinically important difference
in patient management when using the new or existing
test strategies. This type of study may also be useful to
provide evidence that an old test is redundant and
removing it does not compromise patient management.
Estimating the magnitude of changes in patient
management
A test result is only one of several factors influencing
patient management. Therefore, management studies
are designed to estimate the proportion of patients in
w h o mt h ef i n d i n g sf r o mt h en e wt e s tt r a n s l a t et oa n
actual change in management. This quantification allows
researchers to measure and weigh up the consequences
of true and false test results for patients.
By estimating the magnitude of changed manage-
ment, these studies demonstrate the ‘activity’ of the
test on changing management. The review of breast
MRI showed that a proportion, but not all, additional
positive MRI findings lead to more extensive surgery
[16]. Evidently some of these cases do not meet the
decision threshold for an increase in treatment. The
important issue, however, is that we are not sure
whether more extensive surgery improves patient
health outcomes [19].
A study that finds no management change may still
reveal other important attributes of a test outside the
test-treatment pathway, such as reassurance or reduced
test failure rates. A trial that assessed the impact of MRI
and CT in patients with low back pain showed that ima-
ging significantly increased diagnostic confidence with-
out changing treatment plans [20]. Even so, slightly
improved outcomes have been reported in back pain
patients undergoing imaging, which were attributed to
the direct test effect of reassurance rather than indirect
effects through management changes [21].
Patient management studies can also address other
research questions, for example to audit clinician adher-
ence to clinical guidelines. For example, a trial of the
Canadian CT Head Rule showed that the use of this
decision aid did not reduce the rates of CT imaging in
Canadian emergency departments [22].
Study designs
Both experimental and observational study designs can
be used to measure change in patient management. The
quality of the evidence from these studies depends on
how well they are designed to minimise bias. Studies
reporting changes in actual management provide higher
quality evidence than studies relying on hypothetical
planned management.
RCTs with patient management as a primary endpoint
are the optimal design to minimise bias for measure-
ment of the consequences of alternative test strategies
(Figure 3A), because they do not rely on assumptions of
planned management. Such RCTs are suitable for repla-
cement, add-on or triage tests and can also measure any
other important intermediate consequences of the test
procedure, such as test safety or patient acceptability.
This evidence may be instrumental in the planning of
definitive trials of a test. Rules developed for the design
and reporting of treatment trials also apply to trials
reporting on patient management [23]. An example is
the ongoing POC-OP trial, which measures the effec-
tiveness of point-of-care prothrombin time testing to
reduce the administration of blood products during and
after surgery [18]. Patients are randomised to usual care
plus point-of-care testing or usual care only, and the
primary outcome is the relative risk of receiving any
fresh frozen plasma perioperatively. If point-of-care pro-
thrombin time testing in the operation theatre proves to
reduce the administration of fresh frozen plasma, this
may lead to decreased costs and avoid complications
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products.
Despite the important advantages of using randomised
comparisons, the most common type of study used to
measure the impact of test results on patient manage-
ment is the observational ‘diagnostic before-after’ study
(Figure 3B) [4]. These studies are often used to provide
an overview of the impact of test results on patient
management in broad patient groups where multiple
differential diagnoses are considered. Pre- and post-test
management plans, both hypothetical, are recorded to
estimate the potential impact of test results on patient
management. These studies can only be applied to add-
on tests and are prone to bias, foremost because clini-
cians may not use the same caution when defining pre-
test management plans, for example the intent to per-
form surgery, as they do in real-life practice because
they know these plans can be revised once the test
results are available. Measuring actual management in
addition to hypothetical post-test management plans
can assess the extent to which planned management is
put into practice. Fineberg and colleagues used this
design to examine patient management in the study of
cranial CT [3]. Similar studies are found in the current
medical literature to support conclusions about the
effectiveness of PET for various cancers [24-27]. In the
United States, the National Oncologic PET Registry was
established to show whether PET has a similar impact
on intended patient management in previously unfunded
rare cancer types, and to identify variations in the types
of management changes between different malignancies
[28]. PET changed the planned treatment or no-treat-
ment decision in more than a third of tested patients.
PET more commonly led to cancer upstaging due to the
delineation of a greater tumour mass than downstaging.
If the initial plan was a biopsy, potentially three quarters
of these biopsies might be avoided due to PET [25]. The
authors concluded that, in view of its consistent impact
for a wide range of cancers, the use of PET should not
be restricted by cancer type [26].
A related design is epidemiological studies that com-
pare the management of patients in current practice,
which includes the information of a new test, with the
management of historic controls before the test was
R
Existing test
strategy
New test
strategy
Actual
management
Actual
management
Target population
Prior tests
A
Test RCT for patient management
Actual management
Pre-test management plan
Post-test management plan
New test
Target population
Prior tests
Existing test
B
Diagnostic before-after study
Actual management
Reference standard
Target population
Prior tests
Existing test
Pre-test management plan
New test
C
Extended accuracy study
Examples
Point-of-care prothrombin versus 
Clinical judgement:
Avoiding unnecessary transfusion
of fresh frozen plasma
PET added to 
Conventional imaging:
Management of various cancers
Breast MRI added to 
Conventional imaging:
Conversion to more extensive 
surgery
Figure 3 Study designs to assess the impact of tests on patient management. Abbreviations: RCT = randomised controlled trial, R =
randomise, PET = positron emission tomography, MRI = magnetic resonance imaging
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been shown to reduce the downstream use of further
tests compared to a period before the test was available
[29].
Finally, test accuracy studies are sometimes extended
to report on the actual management following testing
when it is uncertain whether true or false additional
findings from the test lead to a change from the
hypothetical pre-test management plan (Figure 3C).
This is only possible when measurement of the refer-
ence standard and patient management do not influence
each other, that is if the reference standard can be per-
formed at or directly after management, or before man-
agement if it is ethical to blind clinicians to the results
of the reference standard, for example in situations
where the results will not be available within the time
frame required for clinical decisions. Extended accuracy
studies can only be used for add-on tests where the pre-
test management plan is clearly determined from the
results of the existing test. Guidelines developed for the
design and reporting of classical accuracy studies also
apply [13]. In the example of breast MRI, this test is
used for the staging of localised breast cancer to detect
additional foci that are occult on conventional imaging.
It has been promoted to improve treatment by identify-
ing women who may benefit from a conversion from
wide local excision to more extensive surgery. As men-
tioned above, a systematic review has confirmed the
higher sensitivity of breast MRI compared with conven-
tional imaging [16]. Some accuracy studies included in
this review also reported on patient management, pro-
viding evidence that some, but not all, additional true
positive MRI findings lead to more extensive surgery.
On the other hand, some patients received more exten-
sive surgery unnecessarily due to false positive MRI
results. The authors concluded that women with true
positive MRI findings who receive more extensive sur-
gery may potentially benefit from better local tumour
control, but trials are needed to confirm these benefits
against the use of standard adjuvant therapy; whereas
those with false positive results have additional biopsies
which may delay treatment and/or result in more breast
tissue excised than necessary, which may lead to a
poorer postoperative cosmetic outcome. A more recent
RCT measuring re-excision rates as a primary endpoint
has now reported that the addition of breast MRI does
not reduce reoperation rates [30].
Conclusions
Patient management can be measured as a surrogate
outcome for test evaluation if its limitations are recog-
nised. This evidence can support recommendations
about the use of a test when assumptions about changes
in management associated with the test are uncertain
and pivotal to conclusions. It can also be incorporated
in decision analysis models designed to weigh up the
potential benefits of a test against its potential harms
and to inform cost-effectiveness analyses.
To date, there are no accepted guidelines for the
design, reporting and appraisal of patient management
studies. Appraisal tools for test accuracy studies have
been adapted to assess the quality of diagnostic before-
after studies [6]; however, readers need to be able to
decide whether patient management is a valid surrogate
for patient health outcomes. Below, we list some princi-
ples to guide clinical researchers toward more transpar-
ent reporting and valid interpretation of these studies.
￿ Studies of patient management must provide a clear
description of the role and position of a test in the clini-
cal pathway, to judge whether the study results are
applicable to the way they are intended to be used in
practice.
￿ The potential consequences of a positive and nega-
tive test result on patient management need to be pre-
specified and the potential patient benefits of these
management changes clearly stated.
￿ Randomised comparisons will provide higher quality
evidence about differences in patient management using
the new test than observational studies.
￿ A detailed description of the study design is crucial
to understand how the authors attempted to minimise
bias, and to decide whether the study results are robust.
￿ Researchers need to report information on how the
data were collected for a study. If actual management
was not recorded, were management plans prospectively
reported on dedicated case report forms or only
assumed based on information from patient charts?
￿ The estimates of changes in management must be
reported contingent on test results; otherwise it is not
possible to conclude to what extent management
changes are dependent on the test.
￿ Patient management studies are easiest to interpret if
it can be assumed that clinicians use all test information
appropriately in a standard way, so that a change in
patient management can be attributed to the test itself
rather than to variations in the clinicians’ behaviour. If
variations between clinicians are anticipated, for exam-
ple due to differences in preference or experience, these
factors can also be measured to assist interpretation of
the results.
In conclusion, researchers should provide clear state-
ments about the assumptions made regarding the effect
of changes in management on patient health outcomes.
These assumptions should be based on a discussion of
the availability and quality of existing evidence for both
test accuracy and the effects of treatment. If the validity
of the underlying assumptions is uncertain, clinicians
should exercise caution when interpreting these studies;
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